BackgroundMany patients with major depressive disorder (MDD) who experience full
symptomatic remission after antidepressant treatment still have residual depressive …

Background Residual symptoms are detrimental to prognosis in major depressive disorder
(MDD); however, little is known about the contribution of each residual symptom in …

Little is known about the quantity or quality of residual depressive symptoms in patients with
major depressive disorder (MDD) who have responded but not remitted with antidepressant …

Treatment for major depressive disorder does not achieve remission in about 50% of
patients following 2 treatment trials. Researchers conducted the Sequenced Treatment …

Objective: Premature attrition from treatment may lead to worse outcomes and compromise
the integrity of clinical trials in major depressive disorder. The purpose of this study was to …

OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat
depression, but the rates, timing, and baseline predictors of remission in “real world” patients …

Context Little is known about selecting among second-step medications for major
depressive disorder after intolerance or lack of remission with an initial selective serotonin …

Major depressive disorder (MDD) is an illness of great morbidity that affects many people
across the world. The current goal for treatment of MDD is to achieve remission (ie, no …

Objective: Phase III clinical trials for depression enroll participants with major depressive
disorder according to stringent inclusion and exclusion criteria. These patients may not be …

Background It has been suggested that clinician‐rated scales and self‐report questionnaires
may be interchangeable in the measurement of depression severity, but it has not been …